Single Dose Study of PF-05230907 in Healthy Japanese Subjects

A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of An Intravenous Bolus Infusion Pf-05230907 In Healthy Japanese Subjects

The purpose of this study is the following:

• To determine the safety and tolerability of single ascending intravenous (IV) doses of PF-05230907 in healthy Japanese subjects.
• To characterize the PK profile of single ascending IV doses of PF-05230907 in healthy Japanese subjects.
• To characterize the PD profiles of single ascending IV doses of PF-05230907 in healthy Japanese subjects.
• To evaluate the immunogenicity of PF-05230907 in healthy Japanese subjects

Inclusion Criteria:

• Healthy male of females
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs) and <120 kg (265 lbs).
• Japanese subjects who have four biologic Japanese grandparents born in Japan.

Exclusion Criteria:

• Pregnant or nursing females.
• Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception.
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease